Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are tuned to interfere with the division process of cancer cells. TTFields are delivered to the region of the cancer using an investigational medical device, called the NovoTTF-100L System. The system is a portable, light-weighted, battery operated device designed to deliver TTFields to the upper torso, the site of pleural mesothelioma. Patients receiving TTFields need to wear four transducer arrays on their upper torso, which deliver the fields non-invasively to this region. The system is intended for continuous home use by patients.
TTFields have been approved by the FDA for treatment of adult patients suffering from recurrent glioblastoma and the NovoTTF-100L has been tested in the past in lung cancer patients. Nevertheless, this investigational system has never before been tested in patients suffering from pleural mesothelioma. Therefore, the safety and efficacy of TTFields in this condition are still unknown, and will be evaluated for the first time in this clinical trial.